Sei Investments Co. Acquires 47,801 Shares of Sanofi (NASDAQ:SNY)

Sei Investments Co. grew its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 644,302 shares of the company's stock after purchasing an additional 47,801 shares during the quarter. Sei Investments Co.'s holdings in Sanofi were worth $31,075,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Boston Partners increased its holdings in Sanofi by 86.4% during the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after buying an additional 2,501,073 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock worth $208,106,000 after purchasing an additional 395,744 shares during the last quarter. Magnetar Financial LLC increased its stake in shares of Sanofi by 104.3% during the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock worth $161,103,000 after purchasing an additional 1,705,148 shares during the last quarter. Natixis Advisors LLC raised its holdings in shares of Sanofi by 1.2% in the 4th quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company's stock worth $140,350,000 after purchasing an additional 35,828 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Sanofi in the fourth quarter valued at approximately $135,933,000. 14.04% of the stock is currently owned by institutional investors.

Remove Ads

Sanofi Stock Performance

Shares of NASDAQ:SNY traded up $0.91 during midday trading on Friday, reaching $55.82. 2,059,619 shares of the company traded hands, compared to its average volume of 2,268,963. The firm's fifty day moving average price is $55.13 and its two-hundred day moving average price is $52.79. The firm has a market capitalization of $141.66 billion, a price-to-earnings ratio of 22.42, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 12 month low of $45.22 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. The Goldman Sachs Group began coverage on Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.